| Filed |
Name |
|
Company |
Pur. £ |
Cur. £ |
P/L % |
MPV* |
|
Apr '12
|
Lord Glendonbrook
|
|
Astrazeneca / LSE:AZN.L |
£2,666.50
|
£14,774.00
|
454.06%
|
£387,841.74
|
|
Apr '10
|
Baroness Noakes
|
|
Astrazeneca / LSE:AZN.L |
£2,938.00
|
£14,774.00
|
402.86%
|
£352,001.36
|
|
Feb '11
|
Lord Wasserman
|
|
Johnson & Johnson / NYQ:JNJ |
£60.93
|
£239.63
|
293.29%
|
£275,301.17
|
|
Mar '14
|
Viscount Eccles
|
|
Astrazeneca / LSE:AZN.L |
£3,876.50
|
£14,774.00
|
281.12%
|
£266,781.89
|
|
Dec '16
|
Lord Burns
|
|
Astrazeneca / LSE:AZN.L |
£4,116.00
|
£14,774.00
|
258.94%
|
£251,258.50
|
|
Jan '13
|
Lord Sassoon
|
|
Johnson & Johnson / NYQ:JNJ |
£72.69
|
£239.63
|
229.66%
|
£230,762.14
|
|
May '11
|
Lord Glendonbrook
|
|
Novartis / NYQ:NVS |
£54.04
|
£161.01
|
197.94%
|
£208,557.47
|
|
May '18
|
Lord Grabiner
|
|
Astrazeneca / LSE:AZN.L |
£5,417.00
|
£14,774.00
|
172.73%
|
£190,913.79
|
|
Apr '17
|
Lord Donoughue
|
|
Novartis / NYQ:NVS |
£66.05
|
£161.01
|
143.78%
|
£170,643.07
|
|
Feb '21
|
Lord Etherton
|
|
Astrazeneca / LSE:AZN.L |
£7,422.00
|
£14,774.00
|
99.06%
|
£139,339.80
|
|
Sep '16
|
Lord Gadhia
|
|
Astrazeneca / LSE:AZN.L |
£5,099.00
|
£10,024.00
|
96.59%
|
£137,611.30**
|
|
Jul '16
|
Lord Lloyd-Webber
|
|
Johnson & Johnson / NYQ:JNJ |
£122.64
|
£239.63
|
95.39%
|
£136,775.12
|
|
Jun '21
|
Lord Morse
|
|
Astrazeneca / LSE:AZN.L |
£8,005.00
|
£14,774.00
|
84.56%
|
£129,191.76
|
|
Apr '21
|
Baroness Deech
|
|
Novartis / NYQ:NVS |
£88.38
|
£161.01
|
82.18%
|
£127,525.46
|
|
Aug '14
|
Lord Carter of Coles
|
|
Johnson & Johnson / NYQ:JNJ |
£100.16
|
£161.55
|
61.29%
|
£112,904.35**
|
|
Nov '23
|
Lord Mance
|
|
Eli Lilly Co / VIE:LLYC.VI |
£557.00
|
£836.90
|
50.25%
|
£105,175.95
|
|
Mar '25
|
Lord Fink
|
|
Johnson & Johnson / NYQ:JNJ |
£161.72
|
£239.63
|
48.18%
|
£103,723.10
|
|
May '25
|
Lord Hayward
|
|
Glaxosmithkline / NYQ:GSK |
£37.37
|
£55.27
|
47.90%
|
£103,529.57
|
|
Dec '16
|
Lord Burns
|
|
Glaxosmithkline / NYQ:GSK |
£37.39
|
£55.27
|
47.82%
|
£103,474.19
|
|
May '23
|
Lord Fink
|
|
Johnson & Johnson / NYQ:JNJ |
£165.03
|
£239.63
|
45.20%
|
£101,642.73
|
|
May '24
|
Lord Goldsmith
|
|
Abbvie / NYQ:ABBV |
£160.81
|
£232.35
|
44.49%
|
£101,141.10
|
|
Nov '23
|
Lord Mance
|
|
Astrazeneca / LSE:AZN.L |
£10,230.00
|
£14,774.00
|
44.42%
|
£101,092.86
|
|
Apr '10
|
Lord Levene of Portsoken
|
|
Glaxosmithkline / NYQ:GSK |
£39.38
|
£55.27
|
40.35%
|
£98,245.30
|
|
Apr '10
|
Baroness Noakes
|
|
Glaxosmithkline / NYQ:GSK |
£39.49
|
£55.27
|
39.96%
|
£97,971.63
|
|
Jan '24
|
Lord Fink
|
|
Roche / EBS:ROG.SW |
£251.85
|
£351.50
|
39.57%
|
£97,697.04
|
|
Apr '17
|
Lord Leigh of Hurley
|
|
Roche / EBS:ROG.SW |
£255.80
|
£351.50
|
37.41%
|
£96,188.43
|
|
May '11
|
Lord Glendonbrook
|
|
Pfizer / NYQ:PFE |
£19.54
|
£26.61
|
36.15%
|
£95,305.14
|
|
Apr '24
|
Lord Mendoza
|
|
Eli Lilly / NYQ:LLY |
£731.33
|
£983.26
|
34.45%
|
£94,113.74
|
|
May '20
|
Lord Deighton
|
|
Astrazeneca / LSE:AZN.L |
£8,361.00
|
£11,236.00
|
34.39%
|
£94,070.09**
|
|
Mar '17
|
Lord Lloyd-Webber
|
|
Glaxosmithkline / NYQ:GSK |
£42.31
|
£55.27
|
30.63%
|
£91,441.74
|
|
May '11
|
Lord Glendonbrook
|
|
Glaxosmithkline / NYQ:GSK |
£42.78
|
£55.27
|
29.20%
|
£90,437.12
|
|
May '24
|
Lord Balfe
|
|
Glaxosmithkline / NYQ:GSK |
£44.02
|
£55.27
|
25.56%
|
£87,889.60
|
|
May '23
|
Lord Fink
|
|
Astrazeneca / LSE:AZN.L |
£11,774.00
|
£14,774.00
|
25.48%
|
£87,835.91
|
|
May '23
|
Lord Londesborough
|
|
Astrazeneca / LSE:AZN.L |
£11,924.00
|
£14,774.00
|
23.90%
|
£86,730.96
|
|
Jan '13
|
Lord Sassoon
|
|
Glaxosmithkline / NYQ:GSK |
£44.75
|
£55.27
|
23.51%
|
£86,455.87
|
|
Apr '24
|
Lord Balfe
|
|
Astrazeneca / LSE:AZN.L |
£12,024.00
|
£14,774.00
|
22.87%
|
£86,009.65
|
|
May '24
|
Lord Goldsmith
|
|
Astrazeneca / LSE:AZN.L |
£12,156.00
|
£14,774.00
|
21.54%
|
£85,075.68
|
|
Aug '17
|
Lord Sterling of Plaistow
|
|
Johnson & Johnson / NYQ:JNJ |
£133.45
|
£157.98
|
18.38%
|
£82,866.99**
|
|
Mar '25
|
Lord Fink
|
|
Roche / EBS:ROG.SW |
£303.00
|
£351.50
|
16.01%
|
£81,204.62
|
|
Nov '25
|
Lord Green of Hurstpierpoint
|
|
Roche / EBS:ROG.SW |
£309.00
|
£351.50
|
13.75%
|
£79,627.83
|
|
Apr '21
|
Lord Grabiner
|
|
Roche / EBS:ROG.SW |
£309.65
|
£351.50
|
13.52%
|
£79,460.68
|
|
Apr '23
|
Lord Grabiner
|
|
Novartis / NYQ:NVS |
£95.80
|
£107.52
|
12.23%
|
£78,563.67**
|
|
Apr '21
|
Lord Farmer
|
|
Glaxosmithkline / NYQ:GSK |
£36.65
|
£40.88
|
11.54%
|
£78,079.12**
|
|
Oct '20
|
Lord Taverne
|
|
Glaxosmithkline / NYQ:GSK |
£37.57
|
£40.95
|
9.00%
|
£76,297.58**
|
|
May '23
|
Lord Leitch
|
|
Astrazeneca / LSE:AZN.L |
£11,820.00
|
£12,340.00
|
4.40%
|
£73,079.53**
|
|
Mar '14
|
Baroness Eccles of Moulton
|
|
Glaxosmithkline / NYQ:GSK |
£53.43
|
£55.27
|
3.44%
|
£72,410.63
|
|
Feb '25
|
Lord Green of Hurstpierpoint
|
|
Roche / EBS:ROG.SW |
£285.70
|
£272.40
|
-4.66%
|
£66,741.33**
|
|
Feb '16
|
Lord Lloyd-Webber
|
|
Pfizer / NYQ:PFE |
£29.02
|
£26.61
|
-8.31%
|
£64,180.64
|
|
Jan '20
|
Lord Gadhia
|
|
Glaxosmithkline / NYQ:GSK |
£46.50
|
£40.95
|
-11.94%
|
£61,645.16**
|
|
Apr '22
|
Lord Cromwell
|
|
Johnson & Johnson / NYQ:JNJ |
£179.90
|
£154.37
|
-14.19%
|
£60,066.15**
|
|
May '23
|
Lord Reay
|
|
Sanofi / NMS:SNY |
£55.11
|
£47.22
|
-14.32%
|
£59,978.23**
|
|
Aug '16
|
Lord Lloyd-Webber
|
|
Eli Lilly / NYQ:LLY |
£80.55
|
£67.15
|
-16.64%
|
£58,355.06**
|
|
Aug '20
|
Lord Reay
|
|
Roche / EBS:ROG.SW |
£315.05
|
£249.80
|
-20.71%
|
£55,502.30**
|
|
Jul '18
|
Lord Glendonbrook
|
|
Bayer / GER:BAYN.DE |
£95.26
|
£37.78
|
-60.35%
|
£27,758.24
|
* Minimum Potential Value based on £70,000.00 invested at time of declaration.
** Interest ceased/exited on filed date.